Payment overview · 2025
General Payments
$151.44
8 reported records · 8 companies
Healthcare provider profile · identity verified
Bryce A Ayers, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WASHINGTON, MO · NPI 1689610446
Verified facts
What the public records show
CMS Open Payments records show Bryce A Ayers, M.D. received $151.44 in general payments during 2025 across 8 reported records.
Lundbeck LLC accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 338 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 25.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.23 | 11.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.06 | 11.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.81 | 11.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.75 | 10.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.68 | 10.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.66 | 10.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.71 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.90 | 7 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $54.20 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
297 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
162 | 161 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
338 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1387 | 354 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1042 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 1009 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 900 | 212 |
| Omeprazole | Omeprazole | 824 | 213 |
| Losartan Potassium | Losartan Potassium | 813 | 195 |
| Lisinopril | Lisinopril | 766 | 200 |
| Tamsulosin Hcl | Tamsulosin Hcl | 571 | 143 |
| Pravastatin Sodium | Pravastatin Sodium | 534 | 119 |
| Gabapentin | Gabapentin | 504 | 113 |
| Tramadol Hcl | Tramadol Hcl | 426 | 115 |
| Duloxetine Hcl | Duloxetine Hcl | 419 | 87 |
| Potassium Chloride | Potassium Chloride | 380 | 83 |
| Furosemide | Furosemide | 367 | 96 |
| Metoprolol Tartrate | Metoprolol Tartrate | 364 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 84 |
| Metformin Hcl | Metformin Hcl | 355 | 95 |
| Sertraline Hcl | Sertraline Hcl | 354 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 346 | 85 |
| Eliquis | Apixaban | 338 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 333 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 332 | 79 |
| Finasteride | Finasteride | 332 | 81 |
| Bupropion Xl | Bupropion Hcl | 322 | 81 |
| Mirtazapine | Mirtazapine | 322 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 317 | 52 |
| Ozempic | Semaglutide | 297 | 57 |
| Carvedilol | Carvedilol | 280 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 65 |
| Jardiance | Empagliflozin | 263 | 57 |
| Allopurinol | Allopurinol | 242 | 61 |
| Simvastatin | Simvastatin | 239 | 63 |
| Lorazepam | Lorazepam | 230 | 76 |
| Alendronate Sodium | Alendronate Sodium | 224 | 61 |
| Trazodone Hcl | Trazodone Hcl | 223 | 63 |
| Prednisone | Prednisone | 217 | 127 |
| Diclofenac Sodium | Diclofenac Sodium | 206 | 49 |
| Meloxicam | Meloxicam | 205 | 47 |
| Alprazolam | Alprazolam | 199 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 74 |
| Xarelto | Rivaroxaban | 190 | 39 |
| Buspirone Hcl | Buspirone Hcl | 189 | 27 |
| Farxiga | Dapagliflozin Propanediol | 186 | 37 |
| Celecoxib | Celecoxib | 174 | 54 |
| Spironolactone | Spironolactone | 163 | 38 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 162 | 161 |
| Paroxetine Hcl | Paroxetine Hcl | 157 | 25 |
| Famotidine | Famotidine | 148 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 34 |
| Clonazepam | Clonazepam | 141 | 27 |
| Metformin Hcl Er | Metformin Hcl | 141 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 38 |
| Mounjaro | Tirzepatide | 129 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 121 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 33 |
| Warfarin Sodium | Warfarin Sodium | 120 | 15 |
| Montelukast Sodium | Montelukast Sodium | 115 | 29 |
| Glimepiride | Glimepiride | 114 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 110 | 29 |
| Atenolol | Atenolol | 107 | 26 |
| Chlorthalidone | Chlorthalidone | 103 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 30 |
| Memantine Hcl Er | Memantine Hcl | 100 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 99 | 98 |
| Irbesartan | Irbesartan | 98 | 24 |
| Pregabalin | Pregabalin | 96 | 20 |
| Repatha Sureclick | Evolocumab | 91 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 27 |
| Myrbetriq | Mirabegron | 86 | 19 |
| Ezetimibe | Ezetimibe | 85 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 83 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 13 |
| Trulicity | Dulaglutide | 76 | 14 |
| Synthroid | Levothyroxine Sodium | 73 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 44 |
| Enalapril Maleate | Enalapril Maleate | 72 | 18 |
| Propranolol Hcl | Propranolol Hcl | 70 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 68 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 20 |
| Lovastatin | Lovastatin | 64 | 17 |
| Ondansetron Odt | Ondansetron | 63 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 52 |
| Methotrexate | Methotrexate Sodium | 61 | 13 |
| Fenofibrate | Fenofibrate | 60 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 56 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Bumetanide | Bumetanide | 53 | 14 |
| Diazepam | Diazepam | 51 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | 13 |
| Baclofen | Baclofen | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 37 |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 14 |
| Hydrocortisone | Hydrocortisone | 35 | 13 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Budesonide Dr | Budesonide | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Folic Acid | Folic Acid | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | 11 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Leflunomide | Leflunomide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Nystatin | Nystatin | 21 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.44 · 8 records | Lundbeck LLC | AIRSUPRA, FREESTYLE LIBRE 3, NURTEC ODT, REXULTI, TZIELD, VRAYLAR, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error